Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Tw0-Period Crossover Study to Assess the Efficacy and Safety of the Ampakine® Compound, CX717, Versus Placebo in Adults With Attention-Deficit Hyperactive Disorder

NCT03375021 is registered in ClinicalTrials.gov with RespireRx as lead sponsor.

NCT NCT03375021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03375021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Tw0-Period Crossover Study to Assess the Efficacy and Safety of the Ampakine® Compound, CX717, Versus Placebo in Adults With Attention-Deficit Hyperactive Disorder
Lead sponsor
RespireRx
Phase
Phase 2
Overall status
Completed
Start date
July 19, 2005
Completion date
January 10, 2006
Enrollment
68 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit hyperactivity disorder